

Market Announcement

29 July 2022

Pacific Edge Limited (ASX: PEB) – Trading Halt

Description

The securities of Pacific Edge Limited ('PEB') will be placed in trading halt at the request of PEB, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 2 August 2022 or when the announcement is released to the market.

Issued by

Zufishan Anjum

Senior Compliance Advisor, Accounting, Listings Compliance (Sydney)



Template for trading halt request (NZX & ASX dual listed issuer)

29th July 2022

To:	ASX Limited	NZ RegCo
	20 Bridge St	11 Cable St
	Sydney NSW 2000	Wellington
	Australia	New Zealand

Request for trading halt: Pacific Edge Limited (ASX Code: PEB: NZX Code: PEB)

We request a trading halt to be applied to our securities PEB under ASX Listing Rule 17.1 and NZX Listing Rule 9.9.1(a) and set out below details of the request as per the rules of each of ASX and NZX.

We would like the trading halt to commence immediately.

Reasons for trading halt:

Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) became aware overnight (NZT) of the inclusion of Cxbladder CPT codes in a draft proposal for a different approach to determine which cancer biomarker tests are eligible for reimbursement by Novitas.

The publication of the proposed approach for Genetic Testing in Oncology is set out in a draft Local Coverage Determination (LCD, DL39365) and a draft Local Coverage Article (LCA, DA59125).

Pacific Edge will provide its shareholders with further clarification of the implications for Pacific Edge once it has received advice from its US legal team and other advisors prior to lifting the current trading halt.

The trading halt will remain in place until a further announcement from PEB on Monday 1 August 2022, with trading expected to resume at market open on Monday, 1 August 2022.

We confirm that we are not aware of any reason why the trading halt should not be granted.

Yours sincerely



Grant Gibson
Chief Financial Officer
P: +64 27 599 9943

OVERVIEW www.pacifiedge.co.nz www.pacifiedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com

Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.